Sales revenue for KRKA totalled almost €460 million between January and March of this year, which is a 6% rise when compared to the same period in 2022. However, their total profit for the year was actually 2% lower, at €89.0 million.

During a recent scheduled meeting, the KRKA’s Supervisory Committee addressed how the company’s finances have progressed throughout Q1.

“Sales revenue for KRKA totalled almost €460 million between January and March of this year“

The company’s CEO, Jože Colarič, explained that during this period, their earnings before interest and tax were positive, and revenue had gone up in five areas, including many of their most important markets.

The lower net income was attributed to a change in the exchange rate making exports more expensive, and an increase in income tax.

The company has invested almost €22 million into their discovery, development, and manufacturing efforts, and has had three additional treatments signed off for launch. Their healthy cash flow has provided an internal source of finance for both day-to-day operations and longer-term growth initiatives, as well as helping achieve their dividend goals.

For 2022, shareholders are set to receive €6.60 per share, which is more than 17% more than 2021. The final decision on this will be made at this year’s annual general meeting at the start of July.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.